Where Nevro Stands With Analysts
Analysts have provided the following ratings for Nevro (NYSE:NVRO) within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
Redburn Partners Downgrades Nevro to Neutral
Redburn Partners downgrades Nevro (NYSE:NVRO) from Buy to Neutral.
10 Biggest Price Target Changes For Tuesday
Keybanc boosted NVIDIA Corporation (NASDAQ: NVDA) price target from $775 to $950. NVIDIA shares rose 0.6% to $824.60 in pre-market trading.
Baird Downgrades Nevro to Neutral, Lowers Price Target to $150
Baird analyst Mike Polark downgrades Nevro (NYSE:NVRO) from Outperform to Neutral and lowers the price target from $188 to $150.
61 Biggest Movers From Yesterday
Gainers
Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
44 Stocks Moving In Monday’s Mid-Day Session
Gainers
Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.
A Look Into Nevro’s Debt
Over the past three months, shares of Nevro (NYSE:NVRO) increased by 18.38%. Before having a look at the importance of debt, let us look at how much debt Nevro has.
10 Biggest Price Target Changes For Monday
Barclays raised the price target for Accenture plc (NYSE: ACN) from $310 to $335. Accenture shares rose 1.1% to close at $294.66 on Friday.